grants a new inhaler patent
Lisbon, 11 September 2013. Hovione announced today that the
European Patent Office has granted a patent for Hovione’s XCaps, a
dry powder inhaler (DPI).
XCaps addresses a pulmonary inhalation market need for a very
inexpensive device which combines high efficiency in powder
dispersion with ease of use. Lung fractions in excess of 70% have
been achieved, from a device which only requires two steps to
inhalation and which only has two components plus a dust cover. This
makes XCaps highly suited for inhalation applications where minimal
training of patients is desirable and has the versatility to treat
almost all pulmonary diseases, including asthma, COPD as well as
infection, which typically require very large dose delivery.
XCaps follows on the heels of another successful Hovione DPI,
TwinCaps«, which was developed specifically for an influenza
application and is licensed to Daiichi Sankyo and Biota for this
application. Hovione is offering XCaps as a part of its inhalation
device portfolio, allowing its integration with a drug product
development program, allowing business partners to take their
candidate drugs from the API stage all the way to the unit dose,
with a single partner.
Peter Villax, Vice-President and co-inventor of the device, said
“We give our customers an edge in speed of development because we
are perhaps the only independent company developing DPIs with
expertise in every aspect of the inhaled drug development process.
Granting of the European Patent on the XCaps inhaler, within 30
months after initial filing, underpins Hovione’s capabilities in
innovation and intellectual property management, to successfully
design, develop and deliver innovative products, namely, a quality
inhalation device, addressing a market need”.
“The XCaps addresses a gap for a simple, easy to use, cost
effective, multiple use, capsule based inhalation device. This
allows our business partners to take advantage of additional patent
protection for their inhalation drug product and effective drug
product life cycle management” said Gonšalo Andrade, Business
Hovione is currently executing inhaled drug development projects
for multiple pharmaceutical companies, involving API process
development, particle engineering, formulation and clinical supplies
and is looking for partners willing to incorporate the XCaps into
their inhalation drug development.
Hovione is a global company with over 50 years’ experience in Active
Pharmaceutical Ingredient and Drug Product Intermediate development
and compliant manufacture. With four FDA inspected sites in the
U.S., China, Ireland, and Portugal, the company focuses on the most
demanding customers in the most regulated markets. Hovione offers
integrated API, particle design, formulation development and GMP
manufacturing. In the inhalation area, Hovione is the only
independent company offering such a broad range of services.
More about XCaps at